Spark Therapeutics is developing curative, one-time gene therapy products with the potential to transform the lives of patients and re-imagine the treatment of debilitating diseases. Spark's lead gene therapy candidate, for RPE65-related blindness, is currently in Phase 3 clinical trials with the potential to be the first approved gene therapy in the United States, and the first treatment to address the significant unmet needs of patients living with blindness due to inherited retinal dystrophies. Additionally, the company has clinical and preclinical programs in other inherited retinal dystrophies and hematological disorders, and a proprietary manufacturing platform that has successfully supported human gene therapy trials across diverse therapeutic areas and routes of administration. Spark's founding team includes scientists who led the movement to develop gene therapy as a new treatment paradigm, establishing clinical proof of concept in the eye and liver and contributing key insights to the field that have resulted in a resurgence of industry interest in gene-based medicines.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/28/14 | $72,800,000 | Series B |
Brookside Capital Children's Hospital of Philadelphia Deerfield Management Company, L.P. Rock Springs Capital Sofinnova Ventures T. Rowe Price Associates Wellington Management Company | undisclosed |
